The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review
Authors
Keywords
-
Journal
ADVANCES IN THERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-22
DOI
10.1007/s12325-020-01379-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunologic correlates of the abscopal effect in a SMARCB1/INI1-negative Poorly Differentiated Chordoma after EZH2 inhibition and radiotherapy
- (2019) Mrinal M. Gounder et al. CLINICAL CANCER RESEARCH
- A patent review of arginine methyltransferase inhibitors (2010-2018)
- (2019) Xiao Li et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- EZH2 inhibitor GSK126 suppresses anti-tumor immunity by driving production of myeloid-derived suppressor cells
- (2019) Shuo Huang et al. CANCER RESEARCH
- INTERIM UPDATE FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
- (2019) F. Morschhauser et al. HEMATOLOGICAL ONCOLOGY
- Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression
- (2019) Cristina Segovia et al. NATURE MEDICINE
- Phase 1 study of the novel enhancer of zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematological and solid tumors
- (2019) Timothy A. Yap et al. CLINICAL CANCER RESEARCH
- 438OMETEOR-1: A phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours
- (2019) L L Siu et al. ANNALS OF ONCOLOGY
- 42OA phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas
- (2018) W Harb et al. ANNALS OF ONCOLOGY
- The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia
- (2018) Eytan M. Stein et al. BLOOD
- A phase 1b/2 study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration resistant prostate cancer (mCRPC).
- (2018) Mary-Ellen Taplin et al. JOURNAL OF CLINICAL ONCOLOGY
- Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
- (2018) Antoine Italiano et al. LANCET ONCOLOGY
- LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity
- (2018) Zahid Q. Bonday et al. ACS Medicinal Chemistry Letters
- TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma
- (2018) Kazuhide Nakayama et al. Oncotarget
- Positive Expression of SMYD2 is Associated with Poor Prognosis in Patients with Primary Hepatocellular Carcinoma
- (2018) Shan-Ru Zuo et al. Journal of Cancer
- Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy
- (2018) Sangeeta Goswami et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.
- (2018) Marjorie Glass Zauderer et al. JOURNAL OF CLINICAL ONCOLOGY
- The Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy
- (2018) Helen Loo Yau et al. TRENDS IN CELL BIOLOGY
- Six Years (2012–2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2‐Pyridone Compounds
- (2018) Rossella Fioravanti et al. CHEMICAL RECORD
- Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1α and APC2 gene expression in non-small cell lung cancer
- (2018) Keqiang Zhang et al. Molecular Cancer
- The chromatin accessibility landscape of primary human cancers
- (2018) M. Ryan Corces et al. SCIENCE
- The Histone H3 Lysine 4 Presenter WDR5 as an Oncogenic Protein and Novel Epigenetic Target in Cancer
- (2018) Kebin Lu et al. Frontiers in Oncology
- EZH2 inhibitors: a patent review (2014-2016)
- (2017) Giulia Stazi et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)
- (2017) Pei-Pei Kung et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy
- (2017) Ying Huang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure-Guided Design of EED Binders Allosterically Inhibiting the Epigenetic Polycomb Repressive Complex 2 (PRC2) Methyltransferase
- (2017) Andreas Lingel et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models
- (2017) Elayne Chan-Penebre et al. MOLECULAR CANCER THERAPEUTICS
- Arginine Methylation: The Coming of Age
- (2017) Roméo S. Blanc et al. MOLECULAR CELL
- Chromatin states define tumour-specific T cell dysfunction and reprogramming
- (2017) Mary Philip et al. NATURE
- An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED
- (2017) Wei Qi et al. Nature Chemical Biology
- The EED protein–protein interaction inhibitor A-395 inactivates the PRC2 complex
- (2017) Yupeng He et al. Nature Chemical Biology
- Identification of H3K4me1-associated proteins at mammalian enhancers
- (2017) Andrea Local et al. NATURE GENETICS
- EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas
- (2017) Faizaan Mohammad et al. NATURE MEDICINE
- PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors
- (2017) Thomas Januario et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance
- (2017) Sheng Yu Ku et al. SCIENCE
- Resistance to checkpoint blockade therapy through inactivation of antigen presentation
- (2017) Moshe Sade-Feldman et al. Nature Communications
- Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma
- (2017) Masayuki Yokoyama et al. Oncotarget
- Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED
- (2017) Ling Li et al. PLoS One
- Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma
- (2017) Allison E. Drew et al. Scientific Reports
- N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer
- (2016) Etienne Dardenne et al. CANCER CELL
- Smyd3 Is a Transcriptional Potentiator of Multiple Cancer-Promoting Genes and Required for Liver and Colon Cancer Development
- (2016) Michalis E. Sarris et al. CANCER CELL
- SETD7 Controls Intestinal Regeneration and Tumorigenesis by Regulating Wnt/β-Catenin and Hippo/YAP Signaling
- (2016) Menno J. Oudhoff et al. DEVELOPMENTAL CELL
- Arginine methyltransferases in normal and malignant hematopoiesis
- (2016) Sarah M. Greenblatt et al. EXPERIMENTAL HEMATOLOGY
- Dynamic Changes in Chromatin Accessibility Occur in CD8 + T Cells Responding to Viral Infection
- (2016) James P. Scott-Browne et al. IMMUNITY
- Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 Inhibitors
- (2016) Scott D. Cowen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas
- (2016) Rishi G. Vaswani et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2
- (2016) Erik Eggert et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting EZH2 in cancer
- (2016) Kimberly H Kim et al. NATURE MEDICINE
- Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5
- (2016) Konstantinos J. Mavrakis et al. SCIENCE
- MTAPdeletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells
- (2016) Gregory V. Kryukov et al. SCIENCE
- The epigenetic landscape of T cell exhaustion
- (2016) D. R. Sen et al. SCIENCE
- Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets
- (2016) Glenn S. Van Aller et al. STRUCTURE
- Turning a Substrate Peptide into a Potent Inhibitor for the Histone Methyltransferase SETD8
- (2016) Russell A. Judge et al. ACS Medicinal Chemistry Letters
- The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer
- (2016) Mei-Ren Pan et al. Oncotarget
- Protein arginine methylation/demethylation and cancer
- (2016) Coralie Poulard et al. Oncotarget
- WDR5 high expression and its effect on tumorigenesis in leukemia
- (2016) Zheng Ge et al. Oncotarget
- MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis
- (2016) Katya Marjon et al. Cell Reports
- The emerging role of lysine methyltransferase SETD8 in human diseases
- (2016) Ciro Milite et al. Clinical Epigenetics
- ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor
- (2016) Zineb Mounir et al. eLife
- MLL1 and MLL1 fusion proteins have distinct functions in regulating leukemic transcription program
- (2016) Jing Xu et al. Cell Discovery
- Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma
- (2016) Satoshi Kawano et al. PLoS One
- Inhibition of H3K9 methyltransferase G9a induces autophagy and apoptosis in oral squamous cell carcinoma
- (2015) Aishu Ren et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma
- (2015) Y. Sun et al. CANCER RESEARCH
- The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond
- (2015) Nicole Stopa et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2
- (2015) Hannah Nguyen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PRMT1 Is a Novel Regulator of Epithelial-Mesenchymal-Transition in Non-small Cell Lung Cancer
- (2015) Sreedevi Avasarala et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response
- (2015) Hsin-Wei Liao et al. JOURNAL OF CLINICAL INVESTIGATION
- Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
- (2015) Dongjun Peng et al. NATURE
- A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models
- (2015) Elayne Chan-Penebre et al. Nature Chemical Biology
- Loss of BAP1 function leads to EZH2-dependent transformation
- (2015) Lindsay M LaFave et al. NATURE MEDICINE
- Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors
- (2015) V Gibaja et al. ONCOGENE
- Overexpression of SMYD3 and matrix metalloproteinase-9 are associated with poor prognosis of patients with gastric cancer
- (2015) Yong Liu et al. TUMOR BIOLOGY
- Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor
- (2015) Lorna H. Mitchell et al. ACS Medicinal Chemistry Letters
- PRMT5 Is Required for Lymphomagenesis Triggered by Multiple Oncogenic Drivers
- (2015) Y. Li et al. Cancer Discovery
- The cancer COMPASS: navigating the functions of MLL complexes in cancer
- (2015) David J. Ford et al. Cancer Genetics
- SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3
- (2015) Filipa Quintela Vieira et al. Oncotarget
- Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs
- (2015) Vanesa Nogales et al. Oncotarget
- Upregulated WDR5 promotes proliferation, self-renewal and chemoresistance in bladder cancer via mediating H3K4 trimethylation
- (2015) Xu Chen et al. Scientific Reports
- Functional Role of G9a Histone Methyltransferase in Cancer
- (2015) Francesco Casciello et al. Frontiers in Immunology
- Epigenetics: Relevance and Implications for Public Health
- (2014) Laura S. Rozek et al. Annual Review of Public Health
- The polycomb repressive complex 2 governs life and death of peripheral T cells
- (2014) Y. Zhang et al. BLOOD
- Genetic Validation of the Protein Arginine Methyltransferase PRMT5 as a Candidate Therapeutic Target in Glioblastoma
- (2014) Fengting Yan et al. CANCER RESEARCH
- Discovery of a Selective, Substrate-Competitive Inhibitor of the Lysine Methyltransferase SETD8
- (2014) Anqi Ma et al. JOURNAL OF MEDICINAL CHEMISTRY
- The emerging roles of DOT1L in leukemia and normal development
- (2014) C M McLean et al. LEUKEMIA
- Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours
- (2014) Marialuisa Sponziello et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
- (2014) S. K. Knutson et al. MOLECULAR CANCER THERAPEUTICS
- A Role for WDR5 in Integrating Threonine 11 Phosphorylation to Lysine 4 Methylation on Histone H3 during Androgen Signaling and in Prostate Cancer
- (2014) Ji-Young Kim et al. MOLECULAR CELL
- Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
- (2014) Hariharan Easwaran et al. MOLECULAR CELL
- SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer
- (2014) Pawel K. Mazur et al. NATURE
- Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type
- (2014) Leora Witkowski et al. NATURE GENETICS
- Recurrent SMARCA4 mutations in small cell carcinoma of the ovary
- (2014) Petar Jelinic et al. NATURE GENETICS
- A rationale to target the SWI/SNF complex for cancer therapy
- (2014) Anja F. Hohmann et al. TRENDS IN GENETICS
- SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma
- (2014) Yong Liu et al. TUMOR BIOLOGY
- Discovery and Development of Potent and Selective Inhibitors of Histone Methyltransferase G9a
- (2014) Ramzi F. Sweis et al. ACS Medicinal Chemistry Letters
- Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth
- (2014) Kimberly H. Kim et al. Cancer Genetics
- Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
- (2013) S. R. Daigle et al. BLOOD
- Phosphorylation of EZH2 Activates STAT3 Signaling via STAT3 Methylation and Promotes Tumorigenicity of Glioblastoma Stem-like Cells
- (2013) Eunhee Kim et al. CANCER CELL
- Deregulated expression of selected histone methylases and demethylases in prostate carcinoma
- (2013) Filipa Quintela Vieira et al. ENDOCRINE-RELATED CANCER
- SMYD3 as an Oncogenic Driver in Prostate Cancer by Stimulation of Androgen Receptor Transcription
- (2013) Cheng Liu et al. JNCI-Journal of the National Cancer Institute
- Targeted disruption of the EZH2–EED complex inhibits EZH2-dependent cancer
- (2013) Woojin Kim et al. Nature Chemical Biology
- Elevated expression of coactivator-associated arginine methyltransferase 1 is associated with early hepatocarcinogenesis
- (2013) SHIGEHIRO OSADA et al. ONCOLOGY REPORTS
- Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
- (2013) S. K. Knutson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tudor: a versatile family of histone methylation ‘readers’
- (2013) Rui Lu et al. TRENDS IN BIOCHEMICAL SCIENCES
- PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer
- (2013) Teruyuki Sato et al. Scientific Reports
- Histone H3 lysine 4 methyltransferases and demethylases in self-renewal and differentiation of stem cells
- (2013) Bingnan Gu et al. Cell and Bioscience
- PRMT4 Blocks Myeloid Differentiation by Assembling a Methyl-RUNX1-Dependent Repressor Complex
- (2013) Ly P. Vu et al. Cell Reports
- The COMPASS Family of Histone H3K4 Methylases: Mechanisms of Regulation in Development and Disease Pathogenesis
- (2012) Ali Shilatifard Annual Review of Biochemistry
- Protein arginine methyltransferase 5 is essential for growth of lung cancer cells
- (2012) Zhongping Gu et al. BIOCHEMICAL JOURNAL
- Histone Lysine Methyltransferase SETD8 Promotes Carcinogenesis by Deregulating PCNA Expression
- (2012) M. Takawa et al. CANCER RESEARCH
- Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation
- (2012) Glenn S. Van Aller et al. Epigenetics
- PRC2 directly methylates GATA4 and represses its transcriptional activity
- (2012) A. He et al. GENES & DEVELOPMENT
- PR-Set7 and H4K20me1: at the crossroads of genome integrity, cell cycle, chromosome condensation, and transcription
- (2012) D. B. Beck et al. GENES & DEVELOPMENT
- G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer
- (2012) Chenfang Dong et al. JOURNAL OF CLINICAL INVESTIGATION
- EZH2 Generates a Methyl Degron that Is Recognized by the DCAF1/DDB1/CUL4 E3 Ubiquitin Ligase Complex
- (2012) Ji Min Lee et al. MOLECULAR CELL
- Dissecting the genomic complexity underlying medulloblastoma
- (2012) David T. W. Jones et al. NATURE
- EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
- (2012) Michael T. McCabe et al. NATURE
- Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia
- (2012) Panagiotis Ntziachristos et al. NATURE MEDICINE
- Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)
- (2012) M. T. McCabe et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Polycomb repressive complex 2 is required for MLL-AF9 leukemia
- (2012) T. Neff et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
- (2012) K. Xu et al. SCIENCE
- Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells
- (2011) S. He et al. BLOOD
- Regulation of chromatin by histone modifications
- (2011) Andrew J Bannister et al. CELL RESEARCH
- Substrate and product specificities of SET domain methyltransferases
- (2011) Paul A. Del Rizzo et al. Epigenetics
- H3K9 methyltransferase G9a and the related molecule GLP
- (2011) Y. Shinkai et al. GENES & DEVELOPMENT
- Protein-arginine Methyltransferase 1 (PRMT1) Methylates Ash2L, a Shared Component of Mammalian Histone H3K4 Methyltransferase Complexes
- (2011) Jill S. Butler et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The histone methyltransferase Set7/9 promotes myoblast differentiation and myofibril assembly
- (2011) Yazhong Tao et al. JOURNAL OF CELL BIOLOGY
- A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells
- (2011) Masoud Vedadi et al. Nature Chemical Biology
- Smyd3 Is Required for the Development of Cardiac and Skeletal Muscle in Zebrafish
- (2011) Tomoaki Fujii et al. PLoS One
- Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation
- (2010) D. B. Yap et al. BLOOD
- Epigenetic Antagonism between Polycomb and SWI/SNF Complexes during Oncogenic Transformation
- (2010) Boris G. Wilson et al. CANCER CELL
- Histone H3 Lysine 79 Methyltransferase Dot1 Is Required for Immortalization by MLL Oncogenes
- (2010) M.-J. Chang et al. CANCER RESEARCH
- Polycomb Group Proteins: Multi-Faceted Regulators of Somatic Stem Cells and Cancer
- (2010) Martin Sauvageau et al. Cell Stem Cell
- SET7/9 mediated methylation of non-histone proteins in mammalian cells
- (2010) Sriharsa Pradhan et al. Epigenetics
- Histone arginine methylation
- (2010) Alessandra Di Lorenzo et al. FEBS LETTERS
- RioK1, a New Interactor of Protein Arginine Methyltransferase 5 (PRMT5), Competes with pICln for Binding and Modulates PRMT5 Complex Composition and Substrate Specificity
- (2010) Gernot Guderian et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- DNA Methylation Increases Nucleosome Compaction and Rigidity
- (2010) John S. Choy et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes
- (2010) Gorica Nikoloski et al. NATURE GENETICS
- Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
- (2010) Ryan D Morin et al. NATURE GENETICS
- Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
- (2010) Thomas Ernst et al. NATURE GENETICS
- Histone H1 variant-specific lysine methylation by G9a/KMT1C and Glp1/KMT1D
- (2010) Thomas Weiss et al. Epigenetics & Chromatin
- Epigenetics in cancer
- (2009) S. Sharma et al. CARCINOGENESIS
- Global Analysis of H3K4 Methylation Defines MLL Family Member Targets and Points to a Role for MLL1-Mediated H3K4 Methylation in the Regulation of Transcriptional Initiation by RNA Polymerase II
- (2009) P. Wang et al. MOLECULAR AND CELLULAR BIOLOGY
- Protein Arginine Methylation in Mammals: Who, What, and Why
- (2009) Mark T. Bedford et al. MOLECULAR CELL
- Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer
- (2009) Gijs van Haaften et al. NATURE GENETICS
- PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing
- (2009) Quan Zhao et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- G9a selectively represses a class of late-replicating genes at the nuclear periphery
- (2009) T. Yokochi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CARM1 Is Required in Embryonic Stem Cells to Maintain Pluripotency and Resist Differentiation
- (2009) Qiang Wu et al. STEM CELLS
- Menin Critically Links MLL Proteins with LEDGF on Cancer-Associated Target Genes
- (2008) Akihiko Yokoyama et al. CANCER CELL
- G9a/GLP complexes independently mediate H3K9 and DNA methylation to silence transcription
- (2008) Makoto Tachibana et al. EMBO JOURNAL
- CARM1 promotes adipocyte differentiation by coactivating PPARγ
- (2008) Neelu Yadav et al. EMBO REPORTS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started